Vertex Versus NHS England: Was The Stand-Off Worth It?

Real World Evidence Key To CF Deal

After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?

Protest_London
Patient groups including #OrkambiNow have kept up the pressure on Vertex and NHS England

After more than three years of disagreement and stalemate, Vertex Pharmaceuticals Inc. and NHS England have agreed an access deal for the company’s cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor).

The row over Orkambi’s £100,000 per patient per year list price became one of the most high profile drug price...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip